Barclays has initiated coverage on Tarsus Pharmaceuticals Inc (TARS) with an Overweight rating, marking the firm's first assessment of the company. This rating reflects Barclays' evaluation of Tarsus's investment potential based on an analysis of its business model, industry dynamics, and growth prospects.
Headquartered in Irvine, California, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates, particularly in eye care. The company’s lead product, XDEMVY, is designed to target and eradicate Demodex blepharitis, a condition caused by mite infestation. Tarsus is also advancing other candidates, including TP-04, a novel ophthalmic gel for Ocular Rosacea, and TP-05, an oral formulation aimed at Lyme disease prophylaxis.
As of December 8, 2025, Tarsus shares are priced at $80.90, with a market capitalization of $3.5 billion. The company has reported a trailing twelve-month EPS of -2.01. Upcoming earnings are anticipated on August 4, 2026, with estimates of $0.40 EPS and $175.5 million in revenue.
Analyst ratings can provide valuable insights, but they are based on assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and market conditions, when making decisions. Tarsus currently holds a consensus rating of Buy, with recent analyst actions reflecting a mix of optimism and cautious assessments.